Multicenter phase II clinical trial of everolimus in Japanese patients with unresectable or metastatic renal cell carcinoma (mRCC) after failure of treatment with first-line tyrosine kinase inhibitor (TKI) therapy.
Seiichiro Ozono
Honoraria - Astellas Pharma; AstraZeneca; Novartis; Pfizer; Sanofi
Research Funding - Astellas Pharma; AstraZeneca; GlaxoSmithKline; Novartis; Pfizer; Sanofi ; Takeda
Masafumi Oyama
No relevant relationships to disclose
Masahiro Nozawa
No relevant relationships to disclose
Kiyohide Fujimoto
No relevant relationships to disclose
Ken Kishida
No relevant relationships to disclose
Noriaki Tokuda
No relevant relationships to disclose
Go Kimura
Honoraria - Novartis
Kazuo Nishimura
No relevant relationships to disclose
Akio Matsubara
No relevant relationships to disclose
Hideyasu Matsuyama
No relevant relationships to disclose
Takayuki Sugiyama
No relevant relationships to disclose
Tomomi Kamba
No relevant relationships to disclose
Haruki Kume
No relevant relationships to disclose
Naoya Masumori
Honoraria - GlaxoSmithKline
Research Funding - Daiichi Sankyo
Mototsugu Oya
Consultant or Advisory Role - Pfizer
Honoraria - Bayer; Pfizer
Hiro-Omi Kanayama
No relevant relationships to disclose
Seiji Naito
Honoraria - Chairman at company organized seminar
Research Funding - Basic Research Fund
Shiro Hinotsu
Honoraria - Novartis
Kojiro Shimozuma
No relevant relationships to disclose
Hideyuki Akaza
Honoraria - Novartis